{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:35:07Z","timestamp":1793118907840,"version":"4.5.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100005971","name":"German Heart Foundation","doi-asserted-by":"publisher","award":["S\/06\/23"],"award-info":[{"award-number":["S\/06\/23"]}],"id":[{"id":"10.13039\/501100005971","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Due to the absence of validated bleeding risk tools in cancer patients undergoing percutaneous coronary intervention (PCI), we aimed to validate an adapted version of the Academic Research Consortium (ARC) High Bleeding Risk (HBR) criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Consecutive patients with active or remission cancer undergoing PCI between 2012 and 2022 at Mount Sinai Hospital (New York, USA) were included. Patients were considered at HBR if they met at least one of the major ARC-HBR criteria, other than cancer, or two minor criteria. The primary endpoint was a composite of periprocedural in-hospital or post-discharge bleeding at 1 year. The key secondary endpoint was major adverse cardiac and cerebrovascular events (MACCEs), including death, myocardial infarction, or stroke. Of the 2007 cancer patients included in this study, 1142 (56.9%) were classified as HBR. Moderate to severe anaemia was the most prevalent major HBR criterion (35%). At 1 year, the incidence of bleeding was significantly higher in HBR compared with non-HBR patients [10.9 vs. 3.9%, adjusted hazard ratio (HR): 2.36, 95% confidence interval (CI): 1.57\u20133.53, P &amp;lt; 0.001], mainly driven by higher periprocedural bleeding. Similarly, HBR patients were at higher risk of MACCE (11.0% vs. 3.2%, adjusted HR: 2.78, 95% CI: 1.72\u20134.47, P &amp;lt; 0.001) and death (8.8% vs. 2.2%, adjusted HR: 3.28, 95% CI: 1.87\u20135.77, P &amp;lt; 0.001) than non-HBR patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>An adapted version of the ARC-HBR criteria, in which cancer is not a major criterion, effectively delineates cancer patients undergoing PCI who are at HBR. Cancer patients at HBR according to this definition also exhibited a higher mortality risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwae399","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T15:27:01Z","timestamp":1734708421000},"page":"537-545","source":"Crossref","is-referenced-by-count":5,"title":["Validation of a high bleeding risk definition in cancer patients undergoing percutaneous coronary intervention"],"prefix":"10.1093","volume":"33","author":[{"given":"Mauro","family":"Gitto","sequence":"first","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]},{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele, MI ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Gilhooley","sequence":"additional","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Smith","sequence":"additional","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9896-403X","authenticated-orcid":false,"given":"Birgit","family":"Vogel","sequence":"additional","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0618-9409","authenticated-orcid":false,"given":"Samantha","family":"Sartori","sequence":"additional","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Bay","sequence":"additional","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Krishnan","sequence":"additional","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Sweeny","sequence":"additional","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Oliva","sequence":"additional","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]},{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele, MI ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Moreno","sequence":"additional","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Maria","family":"Di Muro","sequence":"additional","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parasuram Melarcode","family":"Krishnamoorthy","sequence":"additional","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annapoorna","family":"Kini","sequence":"additional","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Dangas","sequence":"additional","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5546-262X","authenticated-orcid":false,"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samin","family":"Sharma","sequence":"additional","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,21]]},"reference":[{"key":"2026031311370658700_zwae399-B1","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators","year":"2020","journal-title":"Lancet"},{"key":"2026031311370658700_zwae399-B2","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/eurheartj\/ehaa1032","article-title":"Percutaneous coronary intervention in patients with cancer and readmissions within 90 days for acute myocardial infarction and bleeding in the USA","volume":"42","author":"Kwok","year":"2021","journal-title":"Eur Heart J"},{"key":"2026031311370658700_zwae399-B3","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/eurheartj\/ehz851","article-title":"Acute myocardial infarction treatments and outcomes in 6.5 million patients with a current or historical diagnosis of cancer in the USA","volume":"41","author":"Bharadwaj","year":"2020","journal-title":"Eur Heart J"},{"key":"2026031311370658700_zwae399-B4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/jth.12075","article-title":"Coagulation and cancer: biological and clinical aspects","volume":"11","author":"Falanga","year":"2013","journal-title":"J Thromb Haemost"},{"key":"2026031311370658700_zwae399-B5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaccao.2019.11.001","article-title":"Ischemia and bleeding in cancer patients undergoing percutaneous coronary intervention","volume":"1","author":"Ueki","year":"2019","journal-title":"JACC CardioOncol"},{"key":"2026031311370658700_zwae399-B6","first-page":"135","article-title":"Dual antiplatelet therapy and cancer; balancing between ischemic and bleeding risk: a narrative review","volume":"10","author":"Tsigkas","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"key":"2026031311370658700_zwae399-B7","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1016\/j.jacc.2020.03.070","article-title":"Validation of the Academic Research Consortium High Bleeding Risk definition in contemporary PCI patients","volume":"75","author":"Cao","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026031311370658700_zwae399-B8","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention","volume":"140","author":"Urban","year":"2019","journal-title":"Circulation"},{"key":"2026031311370658700_zwae399-B9","first-page":"895","article-title":"SCAI expert consensus statement: evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the Cardiological Society of India, and Sociedad Latino Americana de Cardiolog\u0131a Intervencionista)","volume":"87","author":"Iliescu","year":"2016","journal-title":"Catheter Cardiovasc Interv"},{"key":"2026031311370658700_zwae399-B10","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"2026031311370658700_zwae399-B11","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/ehjqcco\/qcx047","article-title":"Outcome of current and history of cancer on the risk of cardiovascular events following percutaneous coronary intervention: a Kumamoto University Malignancy and Atherosclerosis (KUMA) study","volume":"4","author":"Tabata","year":"2018","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2026031311370658700_zwae399-B12","first-page":"200","article-title":"Influence of a history of cancer on long-term cardiovascular outcomes after coronary stent implantation (an Observation from Coronary Revascularization Demonstrating Outcome Study-Kyoto Registry Cohort-2)","volume":"4","author":"Nakatsuma","year":"2018","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2026031311370658700_zwae399-B13","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jcin.2021.03.049","article-title":"Cancer patients have a higher risk of thrombotic and ischemic events after percutaneous coronary intervention","volume":"14","author":"Guo","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"2026031311370658700_zwae399-B14","doi-asserted-by":"crossref","first-page":"e013000","DOI":"10.1161\/CIRCINTERVENTIONS.122.013000","article-title":"Risk burden of cancer in patients treated with abbreviated dual antiplatelet therapy after PCI: analysis of multicenter controlled high-bleeding risk trials","volume":"17","author":"Campos","year":"2024","journal-title":"Circ Cardiovasc Interv"},{"key":"2026031311370658700_zwae399-B15","author":"Institute NNC"},{"key":"2026031311370658700_zwae399-B16","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jcin.2013.04.016","article-title":"An updated bleeding model to predict the risk of post-procedure bleeding among patients undergoing percutaneous coronary intervention: a report using an expanded bleeding definition from the national cardiovascular data registry CathPCI Registry","volume":"6","author":"Rao","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"key":"2026031311370658700_zwae399-B17","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"key":"2026031311370658700_zwae399-B18","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"2026031311370658700_zwae399-B19","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.jacc.2016.02.064","article-title":"Coronary thrombosis and major bleeding after PCI with drug-eluting stents","volume":"67","author":"Baber","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026031311370658700_zwae399-B20","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"2026031311370658700_zwae399-B21","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1093\/eurheartj\/ehae463","article-title":"Bleeding risk prediction after acute myocardial infarction-integrating cancer data: the updated PRECISE-DAPT cancer score","volume":"45","author":"Dafaalla","year":"2024","journal-title":"Eur Heart J"},{"key":"2026031311370658700_zwae399-B22","first-page":"631","article-title":"Prevalence and outcome of patients with cancer and acute coronary syndrome undergoing percutaneous coronary intervention: a BleeMACS substudy","volume":"7","author":"Iannaccone","year":"2018","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2026031311370658700_zwae399-B23","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/MOH.0000000000000072","article-title":"The coagulopathy of cancer","volume":"21","author":"Falanga","year":"2014","journal-title":"Curr Opin Hematol"},{"key":"2026031311370658700_zwae399-B24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijcard.2021.11.015","article-title":"Validation of the Academic Research Consortium High Bleeding Risk criteria in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis of 10 studies and 67,862 patients","volume":"347","author":"Silverio","year":"2022","journal-title":"Int J Cardiol"},{"key":"2026031311370658700_zwae399-B25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.hjc.2022.04.008","article-title":"Validation of the ARC-HBR criteria in 68,874 patients undergoing PCI: a systematic review and meta-analysis","volume":"66","author":"Montalto","year":"2022","journal-title":"Hellenic J Cardiol"},{"key":"2026031311370658700_zwae399-B26","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1161\/CIRCULATIONAHA.119.041619","article-title":"Long-Term safety and efficacy of durable polymer cobalt\u2013chromium everolimus-eluting stents in patients at high bleeding risk","volume":"141","author":"Sorrentino","year":"2020","journal-title":"Circulation"},{"key":"2026031311370658700_zwae399-B27","doi-asserted-by":"crossref","first-page":"e001779","DOI":"10.1161\/JAHA.115.001779","article-title":"Relationship between cancer and cardiovascular outcomes following percutaneous coronary intervention","volume":"4","author":"Hess","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"2026031311370658700_zwae399-B28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.amjcard.2021.08.021","article-title":"Impact of active and historical cancer on short- and long-term outcomes in patients with acute myocardial infarction","volume":"159","author":"Matsumoto","year":"2021","journal-title":"Am J Cardiol"},{"key":"2026031311370658700_zwae399-B29","first-page":"100607","article-title":"Antiplatelet strategies following PCI: a review of trials informing current and future therapies","volume":"2","author":"Thomas","year":"2023","journal-title":"J Soc Cardiovasc Angiogr Interv"},{"key":"2026031311370658700_zwae399-B30","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/jamacardio.2024.0133","article-title":"Ticagrelor or clopidogrel monotherapy vs dual antiplatelet therapy after percutaneous coronary intervention: a systematic review and patient-level meta-analysis","volume":"9","author":"Valgimigli","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2026031311370658700_zwae399-B31","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1016\/j.jacc.2020.03.008","article-title":"Ticagrelor with or without aspirin in high-risk patients with diabetes mellitus undergoing percutaneous coronary intervention","volume":"75","author":"Angiolillo","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026031311370658700_zwae399-B32","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.jcin.2021.04.043","article-title":"Impact of age on the safety and efficacy of ticagrelor monotherapy in patients undergoing PCI","volume":"14","author":"Angiolillo","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"2026031311370658700_zwae399-B33","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/eurheartj\/ehac706","article-title":"Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials","volume":"44","author":"Costa","year":"2023","journal-title":"Eur Heart J"},{"key":"2026031311370658700_zwae399-B34","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jacc.2022.11.041","article-title":"P2y(12) inhibitor monotherapy or dual antiplatelet therapy after complex percutaneous coronary interventions","volume":"81","author":"Gragnano","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026031311370658700_zwae399-B35","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1161\/CIRCULATIONAHA.117.029289","article-title":"Standardized end point definitions for coronary intervention trials: the Academic Research Consortium-2 consensus document","volume":"137","author":"Garcia-Garcia","year":"2018","journal-title":"Circulation"},{"key":"2026031311370658700_zwae399-B36","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jaccao.2022.01.102","article-title":"Does cardiovascular mortality overtake cancer mortality during cancer survivorship?: an English retrospective cohort study","volume":"4","author":"Strongman","year":"2022","journal-title":"JACC CardioOncol"},{"key":"2026031311370658700_zwae399-B37","doi-asserted-by":"crossref","first-page":"131167","DOI":"10.1016\/j.ijcard.2023.131167","article-title":"Validation of the Academic Research Consortium High Bleeding Risk definition in Thai PCI registry","volume":"388","author":"Roongsangmanoon","year":"2023","journal-title":"Int J Cardiol"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwae399\/61253653\/zwae399.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/33\/4\/537\/61253653\/zwae399.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/33\/4\/537\/61253653\/zwae399.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T15:37:19Z","timestamp":1773416239000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/33\/4\/537\/7930297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,21]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,12,21]]},"published-print":{"date-parts":[[2026,3,13]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwae399","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2024,12,21]]}}}